文献速递肿瘤 PET/CT甲状腺核医学放射性药物与辐射防护

免疫检查点阻断治疗的转移性黑色素瘤患者免疫相关不良事件的定量影像生物标志物:一项先导研究

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-27

该先导研究回顾性分析58例接受抗PD-1或抗CTLA-4免疫检查点抑制剂治疗的转移性黑色素瘤患者的18F-FDG PET/CT图像,用卷积神经网络分割肠道、肺和甲状腺,发现靶器官内18F-FDG摄取SUV百分位数与免疫相关不良事件相关,部分不良事件可在临床症状出现前被检出。

要点

  • 31%(18/58)患者在三靶器官发生免疫相关不良事件:肠道6例、肺5例、甲状腺9例。
  • 识别不良事件的最佳指标:肠道SUV95%的AUROC=0.79,肺SUV95%的AUROC=0.98,甲状腺SUV75%的AUROC=0.88。
  • 部分免疫相关不良事件可在临床症状出现前于18F-FDG PET/CT上检出。

核心结论

  • 免疫相关不良事件受累器官内18F-FDG摄取增高可提供接受免疫检查点抑制剂治疗的黑色素瘤患者发生不良事件的预测信息,是潜在的定量影像生物标志物。
  • 部分免疫相关不良事件可在临床症状出现前于18F-FDG PET/CT上检出。

研究设计与样本

  • 回顾性分析58例接受抗PD-1或抗CTLA-4免疫检查点抑制剂治疗的转移性黑色素瘤患者的18F-FDG PET/CT图像,以评估免疫相关不良事件。
  • 选取最常受免疫相关不良事件影响的肠道、肺和甲状腺三个靶器官,用卷积神经网络分割,并将靶器官内18F-FDG摄取的SUV百分位数与临床不良事件状态进行相关分析。
  • 采用受试者工作特征曲线下面积(AUROC)量化不良事件检测性能,以未发生不良事件的患者建立靶器官18F-FDG摄取的正常范围。

主要发现

  • 31%(18/58)患者在三靶器官发生免疫相关不良事件:肠道6例、肺5例、甲状腺9例。
  • 识别不良事件的最佳百分位数:肠道SUV95%(AUROC=0.79)、肺SUV95%(AUROC=0.98)、甲状腺SUV75%(AUROC=0.88)。
  • 不良事件检测的最佳截断值:肠道SUV95%>2.7 g/mL、肺SUV95%>1.7 g/mL、甲状腺SUV75%>2.1 g/mL。
  • 未发生不良事件患者的SUV百分位数正常范围(95%置信区间):肠道[1.74, 2.86 g/mL]、肺[0.73, 1.46 g/mL]、甲状腺[0.86, 1.99 g/mL]。

关键数值与推荐

  • 肠道免疫相关不良事件识别:最佳百分位数为SUV95%,AUROC=0.79,最佳截断值SUV95%>2.7 g/mL。
  • 肺免疫相关不良事件识别:最佳百分位数为SUV95%,AUROC=0.98,最佳截断值SUV95%>1.7 g/mL。
  • 甲状腺免疫相关不良事件识别:最佳百分位数为SUV75%,AUROC=0.88,最佳截断值SUV75%>2.1 g/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. METHODS: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers - SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs - were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. RESULTS: A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. CONCLUSIONS: Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hribernik N, Huff DT, Studen A, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34958422. doi:10.1007/s00259-021-05650-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。